Mercury Labs, a company in the Pharmaceuticals industry, reported revenue of ₹19 crore and net profit of ₹0.67 crore for the September 2026 quarter.
Mercury Labs (BSE: MERCURYLAB) closed at ₹748.90 on 20 Nov 2026, down 14.2% over the past year. Its market capitalisation is ₹90 crore and it trades at 26.2 times earnings.
Incorporated in 1962, Mercury Laboratories Ltd manufactures and exports Pharmaceutical items of gyno and pediatrics.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.